Managers / Q1 2024 · view latest →
Qiming U.S. Ventures Management, LLC
CIK 0001909617 · 11100 NE 8TH ST., SUITE 200, BELLEVUE, WA, 98004 · (425) 709-0772
Summary
Qiming U.S. Ventures Management, LLC reported $90M in U.S.-listed holdings across 6 positions for Q1 2024.
The portfolio is heavily concentrated: KRRO alone accounts for 36.9% of reported value.
Compared with Q4 2023, the fund opened 1 new position and exited 3.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 88.8% · $80M
- Other · 11.2% · $10M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2023 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| JSPRJASPER THERAPEUTICS INC | NEW | +929.0K | 929.0K | +$27M | $27M |
| ICOSAVAX INC | SOLD OUT | −3.51M | 0 | −$55M | $0 |
| JASPER THERAPEUTICS INC | SOLD OUT | −8.52M | 0 | −$7M | $0 |
| ELEVATION ONCOLOGY INC | SOLD OUT | −2.37M | 0 | −$1M | $0 |
| VENTYX BIOSCIENCES INC | TRIMMED | −274.1K | 412.2K | +$571,904 | $2M |
| TRMLTOURMALINE BIO INC | ADDED | +100.0K | 741.7K | +$185,254 | $17M |
| KRROKORRO BIO INC | HELD | +0 | 368.1K | +$15M | $33M |
| HILLEVAX INC | HELD | +0 | 558.9K | +$324,175 | $9M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2024
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | KRROKORRO BIO INChistory → | COM | 36.93% | $33M | 368.1K |
| 2 | JSPRJASPER THERAPEUTICS INChistory → | COM NEW | 30.41% | $27M | 929.0K |
| 3 | TRMLTOURMALINE BIO INChistory → | COM | 18.94% | $17M | 741.7K |
| 4 | HILLEVAX INC | COM | 10.36% | $9M | 558.9K |
| 5 | VENTYX BIOSCIENCES INC | COM | 2.53% | $2M | 412.2K |
| 6 | KEZAR LIFE SCIENCES INC | COM | 0.83% | $747,166 | 828.7K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q3 2025 | $56M | 4 | Nov 10, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $24M | 6 | Aug 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $23M | 6 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $51M | 6 | Jan 28, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $51M | 6 | Nov 7, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $53M | 6 | Aug 13, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $90M | 6 | May 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $109M | 8 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $75M | 7 | Nov 9, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $95M | 7 | Jul 24, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $83M | 7 | Apr 25, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $76M | 7 | Jan 24, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $69M | 7 | Nov 8, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $72M | 7 | Jul 22, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $106M | 6 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $217M | 6 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.